Tag - MGNX

Markets

Stifel cuts MacroGenics PT to $26 from $44; maintains buy rating

Stifel reduced its price target for MacroGenics (NASDAQ:MGNX) to $26 from $44 but maintained its “buy” rating, citing multiple pipeline updates in the company’s fourth quarter report. The stock closed at $10.49 on Feb...

February 25, 2022

Developments

MacroGenics margetuximab gets FDA orphan drug designation for gastric cancer

MacroGenics’ (NASDAQ:MGNX) margetuximab received FDA orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in a Phase 2/3 trial in...

June 5, 2020

Developments

MacroGenics submits margetuximab BLA to the FDA

MacroGenics (NASDAQ:MGNX) submitted a biologics license application (BLA) for margetuximab for the treatment of patients with metastatic HER2-positive breast cancer. The submission is based on the safety and efficacy...

December 19, 2019

Developments

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

MacroGenics (NASDAQ:MGNX) dosed the first patient in its Phase 2/3 MAHOGANY clinical trial of margetuximab for the treatment of HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial will...

October 25, 2019

Developments

MacroGenics reports positive Phase 3 results in HER2-positive metastatic breast cancer

MacroGenics’ (NASDAQ:MGNX) Phase 3 trial of margetuximab met its first sequential primary endpoint of progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer. The median PFS of patients...

May 16, 2019

Tag - MGNX

Stifel cuts MacroGenics PT to $26 from $44; maintains buy rating

MacroGenics margetuximab gets FDA orphan drug designation for gastric cancer

MacroGenics submits margetuximab BLA to the FDA

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

MacroGenics reports positive Phase 3 results in HER2-positive metastatic breast cancer

General

More